Corilagin alleviates podocyte injury in diabetic nephropathy by regulating autophagy via the SIRT1-AMPK pathway

Figure 1 Effects of corilagin on blood glucose and lipids in diabetic mice. A: Timeline of procedure for corilagin (Cor) intervention; B: Structural formula, molecular weight, chemical formula, and CAS number of Cor. A diabetic nephropathy mouse model was induced by high-fat diet feeding followed by streptozotocin injections. Cor was intraperitoneally injected (30 mg/kg/d) for 12 wk; C: Renal hypertrophy index kidney weight (KW)/body weight (BW) was calculated from KW (mg) divided by BW (g); D: Fasting blood glucose (mmol/L) detected with a glucose meter; E: ELISA analysis of glycosylated hemoglobin (%); F and G: Triglycerides and total cholesterol detected by the GPO-PAP colourimetric method. Data are presented as the mean ± SD (n = 8 in each group). Data were analyzed using one-way ANOVA, and the Bonferroni test was used for the post hoc test. ^aP < 0.001 vs control group; ^bP < 0.001 vs DN group. Cor: Corilagin; DN: Diabetic nephropathy; HFD: High-fat diet; FBG: Fasting blood glucose; TG: Triglycerides; TC: Total cholesterol.